Skip to main content
Premium Trial:

Request an Annual Quote

Correlogic, USU and Jackson Foundation to Develop Prostate Cancer Dx

NEW YORK, May 6 (GenomeWeb News) - Correlogic Systems, the Uniformed Services University of the Health Sciences, and the Henry M. Jackson Foundation for the Advancement of Military Medicine intend to co-develop a blood test for the detection of prostate cancer based on the company's protein pattern-recognition approach, the firm said today.


Two concurrent studies will involve up to 2,000 men with prostate cancer. The first study will use Correlogic's ProteomeDx pattern recognition technology to try to develop a blood test for prostate cancer detection that is more effective thanthe current prostate specific antigen test.


With the current PSA test, approximately 75 percent of men who test positive end up undergoing unnecessary prostate biopsies, according to Correlogic.


In the second study, researchers will try to use the technology to try to develop a test to distinguish between indolent and aggressive prostate cancer.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.